Epilepsy Articles – December 2018

EWCT brings you the latest news on epilepsy-related articles

  1. The development of new drugs is a long, challenging and expensive process. Only one or two compounds in 10,000 tested actually become licensed treatments. A potential new medicine may be rejected at any point in the development process on safety, effectiveness or quality grounds. It takes approximately 10-15 years for a new compound to get from the test tube to the clinic, and according to the Association of the British Pharmaceutical industry, it costs, on average, £1.15 billion. These figures don’t include the research effort that goes on before a new ‘candidate’ compound is found.


  2. Despite the wide availability of anti-epileptic drugs (AEDs), almost one third of patients who are newly diagnosed with epilepsy do not receive immediate treatment, new research from Australia shows.


  3. Over the past decade, social media platforms like Facebook and Twitter have become a central part of everyday life. Despite their massive popularity, however, controversy abounds regarding their impact on mental health and wellbeing.


  4. Epilepsy researchers from around the world have examined the DNA of more than 45 000 people, leading to the discovery of 11 genes associated with the disorder and pointing the way to drugs that might benefit millions of patients who do not respond to existing treatments.


  5. Australian researchers have developed a tiny device that electrically stimulates the brain and could one day be used to treat conditions such as epilepsy and Parkinson’s disease without invasive surgery.